RAD51 and cancer: We also found that B02 efficiently disrupts RAD51 foci formation in MDA-MB-231 cells in mouse xenografts indicating that B02 acts by targeting RAD51 protein invivo. Thus, our current data demonstrate that use of RAD51-specific small molecule inhibitor represents a feasible strategy of a combination anti-cancer therapy.